Android app Apple app link

FDA delays decision of Soleno's Prader-Willi syndrome drug

By Yahoo! Finance   |   1 year ago
FDA delays decision of Soleno's Prader-Willi syndrome drug

The FDA postponed its decision on Soleno Therapeutics' therapy for Prader-Willi syndrome to March 27, 2025, citing a major amendment in the drug application. DCCR aims to address hyperphagia in the rare genetic disorder.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.